Fig. 3.

Adjusted mean change from baseline at end of treatment for vital signs measured by home-based self-monitoring or clinic-based monitoring (safety analysis set): (a) systolic blood pressure; (b) diastolic blood pressure; (c) heart rate. Adjusted change from baseline (mean, SE) generated from an analysis of covariance model with treatment group, sex, age group (<65, ≥65 years), previous overactive bladder medication (yes, no), and geographic region as fixed factors and baseline value as a covariate. Comb, combination of solifenacin+mirabegron; Mira, mirabegron; Soli, solifenacin.